Reference

Peptide-research glossary.

Definitional entries for the compounds, pathways, lab terms, and handling concepts that recur across our product pages, research articles, and reference content. Each entry is anchored to PubMed primary research and linked to the relevant Ronin catalog pages.

Pathways and mechanisms

Receptors, kinases, and signalling.

Receptor classes, signalling kinases, and downstream effectors that recur across the BPC-157, TB-500, and broader peptide-mechanism literatures. The VEGFR2-Akt-eNOS cascade forms the central axis with VEGF as the upstream ligand and angiogenesis as the integrated downstream readout.

Pathway

VEGFR2

Vascular endothelial growth factor receptor 2 — the tyrosine-kinase receptor whose activation underwrites the most-cited BPC-157 angiogenic mechanism. Akt-eNOS downstream signalling.
Pathway

VEGF

Vascular endothelial growth factor — the family of dimeric ligands that bind VEGFR receptor tyrosine kinases. The upstream signal in the canonical BPC-157 angiogenic cascade.
Pathway

Akt signalling

Serine/threonine kinase downstream of PI3K. The gatekeeping node for cell-survival, growth, and metabolic responses, and the downstream node activated when VEGFR2 engages.
Pathway

eNOS

Endothelial nitric oxide synthase — produces nitric oxide from L-arginine on the vascular endothelium. Terminal step in the VEGFR2-Akt cascade and a focal point for peptide-research framing of vascular function.
Pathway

Angiogenesis

Formation of new blood vessels from pre-existing vasculature. The dominant integrated readout in BPC-157 and TB-500 preclinical work, distinguished from vasculogenesis and arteriogenesis.
Pathway

Tyrosine kinase receptor

The receptor class that includes VEGFR2, FGFR, EGFR, IGF-1R, and many others. Cell-surface receptors with intrinsic intracellular kinase domains that phosphorylate tyrosine residues on downstream substrates.
Pathway

PI3K

Phosphatidylinositol 3-kinase — the lipid kinase that generates PIP3 from PIP2 and recruits Akt to the membrane. The upstream lipid-kinase step in the VEGFR2-Akt-eNOS cascade.
Pathway

mTOR

Mechanistic target of rapamycin — serine/threonine kinase integrating growth-factor, nutrient, and energy signals. Sits downstream of Akt in the PI3K-Akt-mTOR cascade.
Signal molecule

Nitric oxide

Small free-radical gas synthesised from L-arginine by nitric oxide synthase enzymes. The terminal output of the eNOS arm in the canonical BPC-157 cascade.
Cell type

Endothelial cell

Flat cells lining the inner surface of blood vessels. The substrate for VEGFR2 expression and the cell type in which canonical BPC-157 and TB-500 vascular signalling is studied.
Pathway

Vasculogenesis

De-novo formation of blood vessels from endothelial precursor cells. Distinct from angiogenesis (sprouting from existing vessels) and arteriogenesis (collateral enlargement).
Receptor

Growth hormone receptor

Cytokine receptor signalling through JAK2-STAT5 — NOT a tyrosine kinase receptor. GHR up-regulation is the canonical mechanistic finding in the BPC-157 tendon-healing literature.
Receptor

GHRH receptor

Class B G-protein-coupled receptor on pituitary somatotrophs. The molecular target of synthetic GHRH analogues including tesamorelin and CJC-1295.
Growth factor

IGF-1

Insulin-like growth factor 1 — principal mediator of growth hormone’s anabolic peripheral-tissue effects. The downstream biomarker readout in GHRH-analogue and GH-secretagogue research.
Kinase

AMPK

AMP-activated protein kinase — cellular energy sensor that activates catabolic and suppresses anabolic pathways under energy stress. The dominant signalling node engaged by MOTS-c.

Compounds and structure

Compounds, fragments, and cell types.

Compound entries for the research peptides in the catalog, structural-class designations, etymology, and the research-model cell types that recur across the literature.

Compound

BPC-157

Synthetic 15-amino-acid peptide. Sequence, chemical identifiers, mechanism summary, and pointers to the deeper research articles. The pentadecapeptide BPC-157 / PL 14736 / Bepecin entry.
Compound

TB-500 (thymosin β4)

Synthetic 17-amino-acid acetylated peptide corresponding to a fragment of thymosin β4. G-actin sequestration and integrin-linked kinase signalling as the dominant mechanistic findings.
Compound

GHK-Cu

1:1 copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine. Studied across dermal wound-healing, skin-regeneration, hair-follicle, and anti-oxidative-stress literatures.
Compound

Ipamorelin

Synthetic pentapeptide growth hormone secretagogue and ghrelin-receptor agonist. Selective for GH release with minimal effect on cortisol, prolactin, or ACTH.
Compound

Tesamorelin

Synthetic 44-amino-acid GHRH analogue with N-terminal trans-3-hexenoyl modification for DPP-IV resistance. The HIV-lipodystrophy clinical-trial literature is the dominant published evidence base.
Compound

CJC-1295 No DAC

Synthetic 29-amino-acid GHRH analogue with protease-resistant N-terminal modifications but without the DAC albumin-binding moiety. Modified GRF 1-29 alias.
Compound

Epithalon

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal-gland peptide epithalamin. Investigated in lifespan, carcinogenesis, and neural-activity preclinical models.
Compound

AOD-9604

Synthetic 16-amino-acid peptide reproducing residues 177-191 of human growth hormone plus N-terminal tyrosine. Lipid-metabolism and joint-research applications.
Compound

MOTS-c

Mitochondrial-derived 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. AMPK-axis signalling drives the metabolic-homeostasis findings.
Coenzyme

NAD+

Nicotinamide adenine dinucleotide — central redox coenzyme in every living cell. Not a peptide; a small-molecule dinucleotide cofactor.
Compound

KPV

Synthetic tripeptide Lys-Pro-Val corresponding to the C-terminal of α-MSH. PepT1-mediated intestinal-epithelial uptake with anti-inflammatory transcriptional responses.
Compound

Selank

Synthetic heptapeptide analogue of tuftsin with C-terminal Pro-Gly-Pro tail for protease resistance. Anxiolytic and BDNF-signalling preclinical research.
Compound

Semax

Synthetic heptapeptide analogue of ACTH(4-10) with C-terminal Pro-Gly-Pro tail. BDNF and TrkB signalling in the hippocampus, with intranasal administration.
Compound

Semaglutide

Long-acting GLP-1 receptor agonist. SUSTAIN, STEP, and SELECT clinical-trial programs across type 2 diabetes, obesity, and cardiovascular outcomes.
Compound

Tirzepatide

Dual incretin-receptor agonist at the GIP and GLP-1 receptors. SURPASS and SURMOUNT clinical-trial programs in type 2 diabetes, obesity, and MASH.
Compound

Triple agonist at GIP, GLP-1, and glucagon receptors. Phase 2 clinical trials in obesity and type 2 diabetes; extends the dual-agonist concept of tirzepatide.
Small molecule

5-Amino-1MQ

Small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT). Research tool for dissecting NNMT-pathway biology in muscle, adipose, and metabolic contexts.
Combination

Combined formulation pairing the amylin analogue cagrilintide with semaglutide. Phase 2 clinical trials in weight management and type 2 diabetes.
Blend

CJC-1295 + Ipamorelin blend

Single-vial co-formulation pairing the short-acting GHRH analogue CJC-1295 No DAC with the selective GH secretagogue ipamorelin. Dual-receptor GH-axis engagement.
Blend

Glow Blend

Three-compound research-supply formulation combining GHK-Cu, BPC-157, and TB-500. Skin and tissue-repair research with three non-overlapping mechanism niches.
Blend

KLOW Blend

Four-compound research-supply formulation extending Glow Blend with the addition of KPV. Four non-overlapping mechanism niches in a single vial.
Etymology

Body Protection Compound

The historical research label for the putative parent gastric protective protein from which the synthetic BPC-157 fragment was derived. Etymology and distinction from the synthetic pentadecapeptide.
Structure

Pentadecapeptide

A peptide of fifteen amino-acid residues. The structural designation used throughout the BPC-157 research literature (“stable gastric pentadecapeptide BPC 157” as the standing reference phrase).
Cell type

Tendon fibroblast

Resident matrix-producing cells of tendon tissue (also called tenocytes). The standard in-vitro model in BPC-157 musculoskeletal research.

Lab and handling terms

Supply form, handling, and analytics.

Supply-form, reconstitution-diluent, storage-and-handling, and analytical-method terms that show up across the catalog and the operational reference content.

Supply form

Lyophilized

Freeze-dried under vacuum to remove water by sublimation. The standard supply form for research-grade peptides. Shelf-stability framing and pointers to reconstitution and storage practice.
Diluent

Bacteriostatic water

Sterile water for injection with 0.9% benzyl alcohol added as a preservative. The standard reconstitution diluent for multi-dose research-peptide workflows.
Diluent

Sterile water for injection

USP-grade water with no added preservative — single-use only. The alternative diluent for compounds incompatible with benzyl alcohol.
Handling

Aliquot

A measured portion drawn from a larger volume. Aliquoting a freshly reconstituted stock into single-use portions is the standard defence against freeze-thaw damage.
Handling

Freeze-thaw cycle

One transition from frozen storage to thawed working temperature and back. Repeated cycles drive aggregation, deamidation, and progressive activity loss in many peptides.
Degradation

Aggregation

Irreversible non-native intermolecular association of peptide molecules into higher-order assemblies. Dominant degradation pathway for peptides in solution.
Logistics

Cold chain

Uninterrupted refrigerated handling, transport, and storage. Operationally relaxed for lyophilized peptides — the dry form is shelf-stable at ambient temperatures during transit.
Packaging

Inert-gas headspace

Replacing the air above a lyophilized peptide in a sealed vial with argon or nitrogen to exclude oxygen and moisture. A foundational element of long-term peptide stability.
Analytics

HPLC purity verification

High-performance liquid chromatography for separating, quantitating, and reporting peptide purity. The industry-standard purity readout on research-peptide certificates of analysis.
Analytics

Mass spectrometry

Identity confirmation by ionising the peptide and measuring mass-to-charge ratio. The identity check that pairs with HPLC purity quantitation on every credible certificate of analysis.
Documentation

Certificate of analysis

Per-batch documentation recording HPLC purity, mass spectrometric identity, and any compound-specific tests for a manufactured batch. Pairs raw analytical traces with headline numbers.

Coverage

What the glossary covers.

The glossary is being built out across several categories: compound entries for each peptide in our catalog, pathway and mechanism entries (the VEGFR2-Akt-eNOS axis above, plus AMPK, mTOR, IGF-1 axis, GHRH receptor, and others that recur in research papers), lab and research terms, reconstitution math, storage and handling, regulatory framings, and adjacent terms that show up in the literature for context. If there’s a term you’d like to see covered, email us via the contact page.